Journal of Applied Biological Chemistry

The Korean Society for Applied Biological Chemistry (한국응용생명화학회)
권호 표지
DOI QR코드

DOI QR Code

Isolation of bacteriophage-resistant Pseudomonas tolaasii strains and their pathogenic characters

박테리오파지 저항성을 갖는 Pseudomonas tolaasii 변이주 분리 및 이들의 병원특성

  • Park, Soo-Jin (Department of Environmental and Biological Chemistry, Chungbuk National University) ;
  • Han, Ji-Hye (Department of Environmental and Biological Chemistry, Chungbuk National University) ;
  • Kim, Young-Kee (Department of Environmental and Biological Chemistry, Chungbuk National University)
  • Received : 2016.09.03
  • Accepted : 2016.09.05
  • Published : 2016.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Bacterial blotch caused by Pseudomonas tolaasii is one of the major diseases of oyster mushroom, Pleurotus ostreatus. Application of bacteriophages is a very useful tool to decrease the density of pathogens and it has been successful to making disease-free cultivation area, known as phage therapy. Effect of phages on pathogen sterilization is very limited to the specific host strains. Minor variations of the host strains may cause changes in phage sensitivity. The phage-resistant strains of P. tolaasii were isolated and their pathogenic characters were investigated to improve the effectiveness of phage therapy. In the phylogenetic analysis, both phage-resistant strains and the corresponding host strains were identical based on the sequence comparison of 16S rRNA genes. The pathogenic characters, such as hemolytic activity and brown blotch formation, were measured on the phage-resistant strains and no correlation between phage-resistance and pathogenic characters was observed. Nevertheless, pathogenic characters were sometimes changed in the phage-resistant strains depending on the host strains. In order to make the phage therapy successful, the bacteriophages having a wide host range should be isolated.

세균성 갈반병은 느타리버섯(Pleurotus ostreatus)의 주된 병중의 하나이다. 박테리오파지를 이용한 파지테라피 방법은 병원균의 농도를 감소시켜 병없는 재배사를 만드는데 성공적이었다. 병원균 사멸을 위한 파지의 이용은 숙주균의 특이성 때문에 매우 제한적 효과를 보이며, 이것은 병원균의 작은 변이에도 파지의 민감성은 크게 감소할 수 있기 때문이다. 본 연구에서는 파지테라피의 효용성을 높이기 위하여 갈반병의 원인균인 P. tolaasii 균주로부터 파지-저항성 변이주를 분리하였고 병원성 특성을 조사하였다. 16S rRNA 유전자의 염기서열 분석을 통한 근연관계 분석에서 파지저항성 균주들은 모두 원래의 숙주균과 일치하였고, 용혈활성이나 갈반형성 능력 등 병원성은 파지저항성 획득과 관련이 없는 것으로 확인되었다. 그럼에도 불구하고, 파지저항성 균주의 다양한 병원성은 균의 종류에 따라 증감이 다르게 나타났다. 따라서, 성공적인 파지테라피를 위해서는 넓은 숙주 범위를 갖는 파지의 분리가 필요하다.

Keywords

References

  1. Abedon ST, Thomas-Abedon C (2010) Phage therapy pharmacology. Curr Pharm Biotechnol 11: 28-47 https://doi.org/10.2174/138920110790725410
  2. Abuladze T, Li M, Menetrez MY, Dean T, Senecal A, Sulakvelidze A (2008) Bacteriophages reduce experimental contamination of hard surfaces, tomato, spinach, broccoli, and ground beef by Escherichia coli O157:H7. Appl Environ Microbiol 74: 6230-6238 https://doi.org/10.1128/AEM.01465-08
  3. David K, Olivia MR. Paul R, Jim O, Aidan C (2011) Development of a broad-host-range phage cocktail for biocontrol. Bioeng Bugs 2: 31-37 https://doi.org/10.4161/bbug.2.1.13657
  4. FDA (2006) Food additives permitted for direct addition to food for human consumption; Bacteriophage preparation. Federal Register 71: 47729-47732
  5. Gandy DG (1968) A technique for screening bacteria causing brown blotch of cultivated mushrooms. Annual Report of the Glasshouse Crops Research Institute for 1967: 150-154
  6. Geels FP, Griensven LD, Rutjens AJ (1991) Chlorine dioxide and the control of bacterial blotch on mushrooms, caused by Pseudomonas tolaasii. In: Maher MJ (ed), Science and Cultivation of Edible Fungi, Balkema Publisher, USA, pp 437-442
  7. Housby JN, Mann NH (2009) Phage therapy. Drug Discov Today 14: 536-540 https://doi.org/10.1016/j.drudis.2009.03.006
  8. Iacobellis NS, Lo Cantore P (1998) Recenti acquisizioni sul determinismo della batteriosi del cardoncello (Pleurotus eryngii). Agricoltura Ricerca 176: 51-54
  9. Julie ES, Alfonso HM, Mourad S, Sylvain M (2013) Revenge of the phages:defeating bacterial defences. Nat Rev Microbiol 11: 675-687 https://doi.org/10.1038/nrmicro3096
  10. Kim MH, Park SW, Kim YK (2011) Bacteriophages of Pseudomonas tolaasii for the biological control of brown blotch disease. J Korean Soc Appl Biol Chem 54: 99-104
  11. Labrie SJ, Samson JE, Moineau S (2010) Bacteriophage resistance mechanisms. Nature Rev Microbiol 8: 317-327 https://doi.org/10.1038/nrmicro2315
  12. Lu TK, Koeris MS (2011) The next generation of bacteriophage therapy. Curr Opi Micorbiol 14: 524-531 https://doi.org/10.1016/j.mib.2011.07.028
  13. Mu LL, Yun YB, Park SJ, Cha JS, Kim YK (2015) Various pathogenic Pseudomonas strains that cause brown blotch disease in cultivated mushroom. J Appl Biol Chem 58: 349-354 https://doi.org/10.3839/jabc.2015.055
  14. Simon JL, Julie ES, Sylvain M (2010) Bacteriophage resistance mechanisms. Nat Rev Microbiol 8: 317-327 https://doi.org/10.1038/nrmicro2315
  15. Skurnik M, Strauch E (2006) Phage therapy: facts and fiction. Int J Med Microbiol 296: 5-14
  16. Yun YB, Park SW, Kim YK (2013) Biological characterization of various strains of Pseudomonas tolaasii that causes brown blotch disease. J Koreans Soc Appl Biol Chem 56: 41-45 https://doi.org/10.1007/s13765-012-2242-y

Cited by

  1. Stability increase in the activity of tolaasin inhibitors under reducing conditions vol.60, pp.4, 2017, https://doi.org/10.3839/jabc.2017.055
  2. Characterization of Phage-Resistant Strains Derived from Pseudomonas tolaasii 6264, which Causes Brown Blotch Disease vol.28, pp.12, 2016, https://doi.org/10.4014/jmb.1809.09023
  3. 100 Years Since Tolaas: Bacterial Blotch of Mushrooms in the 21st Century vol.103, pp.11, 2016, https://doi.org/10.1094/pdis-03-19-0589-fe